 <h1>Rajani Side Effects</h1><p class="drug-subtitle"><b>Generic Name:</b> <i>drospirenone / ethinyl estradiol / levomefolate calcium</i></p><ul class="ddc-anchor-links"><li>Consumer</li>
<li>Professional</li></ul><p class="ddc-notification"><b>Note:</b> This document contains side effect information about drospirenone / ethinyl estradiol / levomefolate calcium. Some of the dosage forms listed on this page <em>may not</em> apply to the brand name Rajani.</p><h2>In Summary</h2><p><b>Common side effects of Rajani include:</b> headache and spotting. <b>Other side effects include:</b> irregular menses and migraine.  See below for a comprehensive list of adverse effects.</p><h2 class="ddc-anchor-offset" id="consumer">For the Consumer</h2><p><i>Applies to drospirenone / ethinyl estradiol / levomefolate calcium: oral tablet</i></p><h3>Warning</h3><p class="blackboxWarning-title">Oral route (Tablet)</p><p>Cigarette smoking increases the risk of serious cardiovascular events from combination oral contraceptives (COC) use. This risk increases with age, particularly in women over 35 years of age, and with the number of cigarettes smoked. For this reason, COCs should not be used by women who are over 35 years of age and smoke.</p><h3>Side effects requiring immediate medical attention</h3><p>Along with its needed effects, drospirenone / ethinyl estradiol / levomefolate calcium may cause some unwanted effects. Although not all of these side effects may occur, if they do occur they may need medical attention.</p><p>
<b>Check with your doctor immediately</b> if any of the following side effects occur while taking drospirenone / ethinyl estradiol / levomefolate calcium:</p><p>
<i>More common</i>
</p><ul>
<li>Breast pain or tenderness</li>
<li>headache, severe and throbbing</li>
<li>heavy non-menstrual vaginal bleeding</li>
<li>irregular menstrual periods</li>
<li>nausea</li>
<li>normal menstrual bleeding occurring earlier, possibly lasting longer than expected</li>
</ul><p>
<i>Less common</i>
</p><ul>
<li>Longer or heavier menstrual periods</li>
<li>unusual tiredness or weakness</li>
<li>vomiting</li>
</ul><p>
<i>Incidence not known</i>
</p><ul>
<li>Chills</li>
<li>clay-colored stools</li>
<li>dark urine</li>
<li>difficulty with breathing</li>
<li>dizziness</li>
<li>fever</li>
<li>headache</li>
<li>itching</li>
<li>loss of appetite</li>
<li>pain in the chest, groin, or legs, especially the calves</li>
<li>rash</li>
<li>slurred speech</li>
<li>stomach pain</li>
<li>sudden loss of coordination</li>
<li>sudden, severe weakness or numbness in the arm or leg</li>
<li>unpleasant breath odor</li>
<li>unusual tiredness or weakness</li>
<li>vision changes</li>
<li>vomiting of blood</li>
<li>yellow eyes or skin</li>
</ul><h3>Side effects not requiring immediate medical attention</h3><p>Some side effects of drospirenone / ethinyl estradiol / levomefolate calcium may occur that usually <b>do not need medical attention</b>. These side effects may go away during treatment as your body adjusts to the medicine. Also, your health care professional may be able to tell you about ways to prevent or reduce some of these side effects.</p><p>Check with your health care professional if any of the following side effects <b>continue or are bothersome</b> or if you have any questions about them:</p><p>
<i>Less common</i>
</p><ul>
<li>Crying</li>
<li>decreased interest in sexual intercourse</li>
<li>delusions of persecution, mistrust, suspiciousness, or combativeness</li>
<li>false or unusual sense of well-being</li>
<li>inability to have or keep an erection</li>
<li>irritability</li>
<li>loss in sexual ability, desire, drive, or performance</li>
<li>mental depression</li>
<li>quick to react or overreact emotionally</li>
<li>rapidly changing moods</li>
<li>weight gain</li>
</ul><p>
<!-- end oral tablet --><div class="related-links"><svg aria-hidden="true" class="ddc-icon ddc-icon-info" focusable="false" height="22" viewbox="0 0 24 24" width="22" xmlns="http://www.w3.org/2000/svg"><path d="M14 2H6c-1.1 0-1.99.9-1.99 2L4 20c0 1.1.89 2 1.99 2H18c1.1 0 2-.9 2-2V8l-6-6zm2 16H8v-2h8v2zm0-4H8v-2h8v2zm-3-5V3.5L18.5 9H13z"></path></svg> <span>Managing side effects <span class="ddc-text-nowrap">(general information)</span></span></div>
<h2 class="ddc-anchor-offset" id="professional">For Healthcare Professionals</h2><p><i>Applies to drospirenone / ethinyl estradiol / levomefolate calcium: oral tablet</i></p><h3>General</h3><p>The more commonly reported adverse events include menstrual irregularities, nausea/vomiting, breast pain/tenderness, and headache/migraine.</p><h3>Cardiovascular</h3><p><b>Postmarketing reports</b>: Venous and arterial thromboembolic events (including pulmonary emboli, deep vein thrombosis, cerebral thrombosis, retinal thrombosis, myocardial infarction and stroke), hypertension (including hypertensive crisis)<sup>[Ref]</sup></p><h3>Genitourinary</h3><p>Combination Oral Contraceptives: </p>
<p>-Very Common (10% or more): Menstrual irregularities (up to 24.9%)</p>
<p>-Frequency not reported: Menstrual irregularities including vaginal hemorrhage (primarily spotting), metrorrhagia, menorrhagia, breast tenderness, decreased libido, unscheduled (breakthrough or intracyclic) bleeding</p><p>The average number of episodes of bleeding per 90 days was 3.2 in Cycles 4 to 6; the average number of bleeding and/or spotting days was 15.1 days.  The intensity of bleeding based on the ratio of spotting-only days versus total bleeding and/or spotting days was 5.2/15.1 day.</p><h3>Gastrointestinal</h3><p><b>Common</b> (1% to 10%): Nausea, vomiting,</p>
<p><b>Postmarketing reports</b>: Gallbladder disease, inflammatory bowel disease<sup>[Ref]</sup></p><h3>Hypersensitivity</h3><p><b>Postmarketing reports</b>: Hypersensitivity including anaphylactic reaction<sup>[Ref]</sup></p><h3>Hepatic</h3><p><b>Postmarketing reports</b>: Liver function disturbances, liver tumors<sup>[Ref]</sup></p><h3>Metabolic</h3><p><b>Postmarketing reports</b>: Hyperkalemia, hypertriglyceridemia, changes in glucose tolerance or effect on peripheral insulin resistance (including diabetes mellitus)<sup>[Ref]</sup></p><h3>Nervous system</h3><p><b>Common</b> (1% to 10%): Migraine, headaches<sup>[Ref]</sup></p><h3>Ocular</h3><p><b>Postmarketing reports</b>: Retinal thrombosis<sup>[Ref]</sup></p><h3>Psychiatric</h3><p><b>Frequency not reported</b>: Irritability, depression, affect lability<sup>[Ref]</sup></p><h3>Oncologic</h3><p><b>Frequency not reported</b>: Cervix carcinoma stage 0 </p>
<p><b>Postmarketing reports</b>: Cervical dysplasia<sup>[Ref]</sup></p><h3>Musculoskeletal</h3><p><b>Postmarketing reports</b>: Systemic lupus erythematosus<sup>[Ref]</sup></p><h3>Dermatologic</h3><p><b>Postmarketing reports</b>: Chloasma, angioedema, erythema nodosum, erythema multiforme<sup>[Ref]</sup></p><h3>Other</h3><p><b>Common</b> (1% to 10%): Fatigue</p><div class="referenceList"><h4 id="refs">References</h4><p id="ref_1">1. "Product Information. Beyaz (drospirenone/ethinyl estradiol/levomefolate)." Bayer Pharmaceutical Inc, West Haven, CT. </p></div>
<div class="more-resources" id="moreResources">
<h2>More about Rajani (drospirenone / ethinyl estradiol / levomefolate calcium)</h2>
<ul class="more-resources-list more-resources-list-general">
<li>During Pregnancy</li>
<li>Dosage Information</li>
<li>Drug Images</li>
<li>Drug Interactions</li>
<li>5 Reviews</li>
<li>FDA Alerts (3)</li>
</ul>
<h3>Consumer resources</h3>
<dl class="more-resources-other-brands more-resources-other-brands-consumer"><dt>Other brands</dt><dd>Beyaz, Safyral</dd></dl>
<h3>Professional resources</h3>
<ul class="more-resources-list more-resources-list-professional">
<li>Prescribing Information</li>
</ul>
<h3>Related treatment guides</h3>
<ul class="more-resources-list more-resources-list-conditions">
<li>Acne</li>
<li>Birth Control</li>
<li>Premenstrual Dysphoric Disorder</li>
</ul>
</div>
<h2>Further information</h2><p class="ddc-disclaimer">Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.</p>
<p>Some side effects may not be reported. You may report them to the FDA.</p>
<p class="ddc-disclaimer-link">Medical Disclaimer</p>
<script>
function showRefs(refs) {
	if (!document.querySelectorAll) {
		return;
	}

	var referenceIds = refs ? refs.split(',') : [];
	var referenceTitle = referenceIds.length
		 ? "References relevant to chosen section <span class='ddc-text-size-small font-weight-normal'>(<a href='#refs' onclick='showRefs(\"\"); return false;'>Show all references</a>)</span>"
		 : "References";
	document.getElementById('refs').innerHTML = referenceTitle;

	// Show/hide reference items
	var referenceList = document.querySelectorAll('.referenceList p');
	referenceList.forEach(function(item) {
		var id = item.id.replace('ref_', '');
		if (!referenceIds.length || referenceIds.includes(id)) {
			item.style.display = 'block';
		}
		else {
			item.style.display = 'none';
		}
	});
}
</script>
</p><h2 class="ddc-anchor-offset" id="professional">For Healthcare Professionals</h2><p><i>Applies to drospirenone / ethinyl estradiol / levomefolate calcium: oral tablet</i></p><h3>General</h3><p>The more commonly reported adverse events include menstrual irregularities, nausea/vomiting, breast pain/tenderness, and headache/migraine.</p><h3>Cardiovascular</h3><p><b>Postmarketing reports</b>: Venous and arterial thromboembolic events (including pulmonary emboli, deep vein thrombosis, cerebral thrombosis, retinal thrombosis, myocardial infarction and stroke), hypertension (including hypertensive crisis)<sup>[Ref]</sup></p><h3>Genitourinary</h3><p>Combination Oral Contraceptives: </p><p>-Very Common (10% or more): Menstrual irregularities (up to 24.9%)</p><p>-Frequency not reported: Menstrual irregularities including vaginal hemorrhage (primarily spotting), metrorrhagia, menorrhagia, breast tenderness, decreased libido, unscheduled (breakthrough or intracyclic) bleeding</p><p>The average number of episodes of bleeding per 90 days was 3.2 in Cycles 4 to 6; the average number of bleeding and/or spotting days was 15.1 days.  The intensity of bleeding based on the ratio of spotting-only days versus total bleeding and/or spotting days was 5.2/15.1 day.</p><h3>Gastrointestinal</h3><p><b>Common</b> (1% to 10%): Nausea, vomiting,</p><p><b>Postmarketing reports</b>: Gallbladder disease, inflammatory bowel disease<sup>[Ref]</sup></p><h3>Hypersensitivity</h3><p><b>Postmarketing reports</b>: Hypersensitivity including anaphylactic reaction<sup>[Ref]</sup></p><h3>Hepatic</h3><p><b>Postmarketing reports</b>: Liver function disturbances, liver tumors<sup>[Ref]</sup></p><h3>Metabolic</h3><p><b>Postmarketing reports</b>: Hyperkalemia, hypertriglyceridemia, changes in glucose tolerance or effect on peripheral insulin resistance (including diabetes mellitus)<sup>[Ref]</sup></p><h3>Nervous system</h3><p><b>Common</b> (1% to 10%): Migraine, headaches<sup>[Ref]</sup></p><h3>Ocular</h3><p><b>Postmarketing reports</b>: Retinal thrombosis<sup>[Ref]</sup></p><h3>Psychiatric</h3><p><b>Frequency not reported</b>: Irritability, depression, affect lability<sup>[Ref]</sup></p><h3>Oncologic</h3><p><b>Frequency not reported</b>: Cervix carcinoma stage 0 </p><p><b>Postmarketing reports</b>: Cervical dysplasia<sup>[Ref]</sup></p><h3>Musculoskeletal</h3><p><b>Postmarketing reports</b>: Systemic lupus erythematosus<sup>[Ref]</sup></p><h3>Dermatologic</h3><p><b>Postmarketing reports</b>: Chloasma, angioedema, erythema nodosum, erythema multiforme<sup>[Ref]</sup></p><h3>Other</h3><p><b>Common</b> (1% to 10%): Fatigue</p><p id="ref_1">1. "Product Information. Beyaz (drospirenone/ethinyl estradiol/levomefolate)." Bayer Pharmaceutical Inc, West Haven, CT. </p><h2>More about Rajani (drospirenone / ethinyl estradiol / levomefolate calcium)</h2><ul class="more-resources-list more-resources-list-general">
<li>During Pregnancy</li>
<li>Dosage Information</li>
<li>Drug Images</li>
<li>Drug Interactions</li>
<li>5 Reviews</li>
<li>FDA Alerts (3)</li>
</ul><h3>Consumer resources</h3><h3>Professional resources</h3><ul class="more-resources-list more-resources-list-professional">
<li>Prescribing Information</li>
</ul><h3>Related treatment guides</h3><ul class="more-resources-list more-resources-list-conditions">
<li>Acne</li>
<li>Birth Control</li>
<li>Premenstrual Dysphoric Disorder</li>
</ul><h2>Further information</h2><p class="ddc-disclaimer">Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.</p><p>Some side effects may not be reported. You may report them to the FDA.</p><p class="ddc-disclaimer-link">Medical Disclaimer</p>